The U.S. direct-to-consumer laboratory testing market is projected to grow from USD 1.17 billion in 2025 to around USD 2.62 billion by 2035, at a CAGR of 8.40%. This growth is fueled by increasing demand for convenient, at-home testing options, advancements in diagnostic technologies, and rising consumer awareness about health management.

U.S. Direct-To-Consumer Laboratory Testing Market Statical Scope

The U.S. direct-to-consumer (DTC) laboratory testing market is rapidly expanding. In the U.S., the market is expanding due to rising consumer interest in ancestry, heritage, and genetic identity insights. Increased awareness of personalized health, wellness, and preventive care is driving demand for at-home DNA testing kits. Advances in affordable sequencing technologies, user-friendly collection methods, and online result platforms have made testing more accessible. Additionally, marketing campaigns and partnerships with health and wellness brands further encourage adoption, positioning demographic testing as a popular segment in the U.S. DTC market.

U.S. Direct-To-Consumer Laboratory Testing Market Share, By Product, 2025 (%)

• Routine clinical laboratory testing- Routine clinical laboratory testing dominates the market, with a share of 58%, driven by strong demand for regular health monitoring and convenient at-home testing solutions across a wide range of common conditions.
• Medical genetic laboratory testing- Medical genetic laboratory testing holds a significant share of 42% of the market, supported by increasing adoption of personalized medicine and growing interest in genetic insights.

U.S. Direct-To-Consumer Laboratory Testing Market Share, By Test Type, 2025 (%)

• Routine testing- Routine testing leads the market with a share of 20%, driven by increasing demand for general health check-ups and ongoing monitoring through accessible at-home solutions.
• Genetic testing- Genetic testing holds a notable share of 18% of the market, supported by rising consumer interest in personalized health insights and disease predisposition analysis.
• Disease risk assessment testing- Disease risk assessment testing accounts for 16% of the market, gaining traction due to growing focus on preventive healthcare and early identification of potential health risks.
• Cancer testing- Cancer testing represents 14% of the market, driven by increasing awareness and demand for early detection and screening solutions.

U.S. Direct-To-Consumer Laboratory Testing Market Share, By Sample Type, 2025 (%)

• Blood- Blood-based testing dominates the market, with a share of 46%, driven by its high accuracy, reliability, and wide applicability across various diagnostic tests.
• Saliva- Saliva-based testing holds a significant share of 24% of the market, supported by its non-invasive nature and increasing use in genetic and certain specialized tests.
• Urine- Urine-based testing accounts for 22% of the market, driven by ease of collection and suitability for routine diagnostics.

Top Companies in the U.S. Direct-To-Consumer Laboratory Testing Market

• Any Lab Test Now, Inc.
• Color Genomics, Inc
• Counsyl, Inc.
• DanteLabs Inc.
• Direct Laboratory Services, LLC
• Eastern Biotech & Life Sciences
• EasyDNA
• EverlyWell, Inc.,
• Full Genomes Corporation, Inc.
• Gene by Gene, Ltd.
• Genecodebook Oy
• Genesis Healthcare Co.
• Genetrainer
• GHC Genetics UK
• HealthCheckUSA
• Home Access Health Corporation
• International Biosciences
• Laboratory Corporation of America Holdings
• LetsGetChecked, Inc.
• Mapmygenome India Limited

Segments Covered in the Report

By Product

• Medical Genetic Laboratory Testing
• Routine Clinical Laboratory Testing

By Test Type

• Genetic Testing
• Cancer
• Diabetes Testing
• Disease Risk Assessment Testing
• COVID-19
• Routine testing
• Sexually Transmitted Disease Testing

By Sample Type

• Blood
• Urine
• Saliva
• Others